German Biotech's $6.4M Seed Could Redefine Heart Disease Treatment

Jan de Vries · 2026-08-28

There's a new player in the European biotech scene, and they're tackling one of healthcare's biggest challenges with a fresh approach. Revier Therapeutics, a startup based in Heidelberg, Germany, just launched publicly and closed a significant seed funding round. The company secured $6.4 million to advance its pipeline of novel therapies for cardiometabolic diseases. This isn't just another funding announcement. It's about a potential shift in how we treat conditions like heart failure. Millions of patients live with limited options, and Revier's team believes they've found a more precise biological target. ### The Funding and the Backers The $6.4 million seed round was led by the KHAN Technology Transfer Fund II. They weren't alone. A coalition of investors joined in, including High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. This kind of regional and specialist backing is a strong signal. It shows that experienced life science investors see genuine potential in the science. Michael Hamacher from KHAN put it simply: the company's strategy has a "unique opportunity to deliver disease-modifying medicines and reshape the standard of care." ### The Science Behind the Startup So, what's the big idea? Revier is focusing on a specific family of enzymes called class IIa histone deacetylases, or HDACs. Think of them like master switches inside cells that can influence many disease processes. Here's the problem with older approaches: early HDAC inhibitors were like using a sledgehammer. They hit multiple targets, which often led to harsh side effects that limited how much medicine a patient could tolerate. Revier's approach is more like a scalpel. Their orally available small molecules are designed to be selective. - They aim to inhibit only the disease-driving activity of class IIa HDACs. - They try to preserve the healthy, essential functions these enzymes perform. - They avoid affecting the related class I HDACs altogether. Prof. Johannes Backs, the company's scientific founder, explained that this precision is key to being effective while maintaining a much better safety profile. ### The Road Ahead for Patients The initial targets are two major cardiometabolic conditions where new treatments are desperately needed: heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). Prof. Eva van Rooij, the CEO, framed the mission clearly. She said the next generation of medicines must "address the underlying disease-driving biology" to create long-term solutions. Revier's goal is to translate the promise of class IIa HDAC inhibition from a lab concept into real clinical programs. The new capital will fuel their preclinical work on these lead programs and help build out the team's operational and clinical capabilities. It's the first critical step on a long path, but it's a step that has attracted serious attention and investment. For professionals watching the European startup landscape, especially in deep tech and biotech, Revier Therapeutics is a name to remember. Their progress could signal a new direction for treating chronic, widespread diseases that affect millions.